Rivipansel - GlycoMimetics/Pfizer

Drug Profile

Rivipansel - GlycoMimetics/Pfizer

Alternative Names: GM-1070; GMI-1070; PF-06460031; PF-6460031

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlycoMimetics
  • Developer GlycoMimetics; Pfizer
  • Class Anti-inflammatories; Antianaemics; Antineoplastics; Glycolipids; Naphthalenesulfonates; Pyrimidines; Small molecules
  • Mechanism of Action E-selectin inhibitors; L-selectin inhibitors; P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sickle cell anaemia
  • No development reported Haematological malignancies

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Haematological-malignancies(Combination therapy) in USA (IV, Infusion)
  • 23 Mar 2017 Pfizer completes a phase I pharmacokinetics trial in Healthy volunteers and subjects with hepatic impairment in USA (NCT02871570)
  • 16 Mar 2017 Pfizer completes a phase I trial for Health volunteers in USA (NCT02998099)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top